Compare Viatris Inc (VTRS) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Williams Companies Inc — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 4.4× Viatris Inc's market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Williams Companies Inc for 58 Days on average.
| VTRS | WMB | |
|---|---|---|
Market Cap | $20.03B | $88.48B |
Volume | 14,109,977 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $18.27 | $79.40 |
52-Week Low | $9.74 | $56.51 |
Typical Hold Time | 57 Days | 58 Days |
Enterprise Value | $32.15B | $119.11B |
Dividend Yield | 2.75% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
WMB trades at $72.34, up 1.23% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while technical indicators signal bullish momentum with support at $71-72 levels. The company benefits from natural gas demand growth driven by AI data center expansion and maintains stable fee-based revenue streams.
Outlook remains positive with 79% analyst buy ratings and $87.27 consensus target, representing 21% upside. Key opportunities include AI-driven natural gas demand and strategic acquisitions, while risks involve energy market volatility and high debt levels. The stock offers compelling value with strong cash flow generation and dividend growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
